Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression

Minehiko Inomata; Naoki Takata; Isami Mizushima; Kenji Azechi; Kana Hayashi; Kotaro Tokui; Chihiro Taka; Seisuke Okazawa; Kenta Kambara; Shingo Imanishi; Toshiro Miwa; Ryuji Hayashi; Shoko Matsui; Kazuyuki Tobe

doi:10.21873/cdp.10023

Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression

Minehiko Inomata^*, Naoki Takata, Isami Mizushima, Kenji Azechi, Kana Hayashi, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background/Aim: We conducted a retrospective analysis of the survival durations of 25 patients diagnosed as having non-squamous cell non-small cell lung cancer with negative or low tumor programmed death-ligand 1 (PD-L1) expression treated with immune checkpoint inhibitor (ICI) monotherapy. Patients and Methods: The progression-free (PFS) and overall (OS) survival were calculated from the initiation of ICI monotherapy. The association between the patient characteristics and the PFS was analyzed using Cox proportional hazards model. Results: The median PFS was 2.6 months, and the 12-month PFS rate was 9.3%. The median OS was 5.5 months, and the 12-month OS rate was 39.8%. A Cox proportional hazards model identified the neutrophil/lymphocyte ratio and presence of liver metastasis as being significantly associated with PFS. Conclusion: Our findings suggest that a subset of patients with non-squamous cell non-small cell lung cancer who show negative or low tumor PD-L1 expression could benefit from ICI monotherapy.

Original language	English
Pages (from-to)	173-177
Number of pages	5
Journal	Cancer Diagnosis and Prognosis
Volume	1
Issue number	3
DOIs	https://doi.org/10.21873/cdp.10023
State	Published - 2021

Keywords

Immune checkpoint inhibitor
lung cancer
PD-L1
survival

ASJC Scopus subject areas

Cancer Research
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/cdp.10023

Cite this

@article{611921df95d94b59b431bd876f9e931a,

title = "Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression",

abstract = "Background/Aim: We conducted a retrospective analysis of the survival durations of 25 patients diagnosed as having non-squamous cell non-small cell lung cancer with negative or low tumor programmed death-ligand 1 (PD-L1) expression treated with immune checkpoint inhibitor (ICI) monotherapy. Patients and Methods: The progression-free (PFS) and overall (OS) survival were calculated from the initiation of ICI monotherapy. The association between the patient characteristics and the PFS was analyzed using Cox proportional hazards model. Results: The median PFS was 2.6 months, and the 12-month PFS rate was 9.3%. The median OS was 5.5 months, and the 12-month OS rate was 39.8%. A Cox proportional hazards model identified the neutrophil/lymphocyte ratio and presence of liver metastasis as being significantly associated with PFS. Conclusion: Our findings suggest that a subset of patients with non-squamous cell non-small cell lung cancer who show negative or low tumor PD-L1 expression could benefit from ICI monotherapy.",

keywords = "Immune checkpoint inhibitor, lung cancer, PD-L1, survival",

author = "Minehiko Inomata and Naoki Takata and Isami Mizushima and Kenji Azechi and Kana Hayashi and Kotaro Tokui and Chihiro Taka and Seisuke Okazawa and Kenta Kambara and Shingo Imanishi and Toshiro Miwa and Ryuji Hayashi and Shoko Matsui and Kazuyuki Tobe",

note = "Publisher Copyright: {\textcopyright} 2021 International Institute of Anticancer Research www.iiar-anticancer.org.",

year = "2021",

doi = "10.21873/cdp.10023",

language = "英語",

volume = "1",

pages = "173--177",

journal = "Cancer Diagnosis and Prognosis",

issn = "2732-7787",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression

AU - Inomata, Minehiko

AU - Takata, Naoki

AU - Mizushima, Isami

AU - Azechi, Kenji

AU - Hayashi, Kana

AU - Tokui, Kotaro

AU - Taka, Chihiro

AU - Okazawa, Seisuke

AU - Kambara, Kenta

AU - Imanishi, Shingo

AU - Miwa, Toshiro

AU - Hayashi, Ryuji

AU - Matsui, Shoko

AU - Tobe, Kazuyuki

PY - 2021

Y1 - 2021

N2 - Background/Aim: We conducted a retrospective analysis of the survival durations of 25 patients diagnosed as having non-squamous cell non-small cell lung cancer with negative or low tumor programmed death-ligand 1 (PD-L1) expression treated with immune checkpoint inhibitor (ICI) monotherapy. Patients and Methods: The progression-free (PFS) and overall (OS) survival were calculated from the initiation of ICI monotherapy. The association between the patient characteristics and the PFS was analyzed using Cox proportional hazards model. Results: The median PFS was 2.6 months, and the 12-month PFS rate was 9.3%. The median OS was 5.5 months, and the 12-month OS rate was 39.8%. A Cox proportional hazards model identified the neutrophil/lymphocyte ratio and presence of liver metastasis as being significantly associated with PFS. Conclusion: Our findings suggest that a subset of patients with non-squamous cell non-small cell lung cancer who show negative or low tumor PD-L1 expression could benefit from ICI monotherapy.

AB - Background/Aim: We conducted a retrospective analysis of the survival durations of 25 patients diagnosed as having non-squamous cell non-small cell lung cancer with negative or low tumor programmed death-ligand 1 (PD-L1) expression treated with immune checkpoint inhibitor (ICI) monotherapy. Patients and Methods: The progression-free (PFS) and overall (OS) survival were calculated from the initiation of ICI monotherapy. The association between the patient characteristics and the PFS was analyzed using Cox proportional hazards model. Results: The median PFS was 2.6 months, and the 12-month PFS rate was 9.3%. The median OS was 5.5 months, and the 12-month OS rate was 39.8%. A Cox proportional hazards model identified the neutrophil/lymphocyte ratio and presence of liver metastasis as being significantly associated with PFS. Conclusion: Our findings suggest that a subset of patients with non-squamous cell non-small cell lung cancer who show negative or low tumor PD-L1 expression could benefit from ICI monotherapy.

KW - Immune checkpoint inhibitor

KW - lung cancer

KW - PD-L1

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85132267692&partnerID=8YFLogxK

U2 - 10.21873/cdp.10023

DO - 10.21873/cdp.10023

M3 - 学術論文

AN - SCOPUS:85132267692

SN - 2732-7787

VL - 1

SP - 173

EP - 177

JO - Cancer Diagnosis and Prognosis

JF - Cancer Diagnosis and Prognosis

IS - 3

ER -

Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this